STAT

Amicus Therapeutics acquires portfolio of gene therapies targeting neurologic disorders

Source: Eric Piermont/AFP/Getty Images

Amicus Therapeutics is expanding the focus its drug development work with the purchase of a portfolio of early-stage gene therapies targeting rare neurologic diseases, the company announced Thursday.

Two of the 10 gene therapies programs being acquired by Amicus have already entered human clinical trials as potential, one-time cures for different forms

You're reading a preview, sign up to read more.

More from STAT

STAT7 min readPsychology
Do Elon Musk’s Brain-decoding Implants Have Potential? Experts Say They Just Might
Do Elon Musk’s brain-decoding implants have potential? Independent experts consulted by STAT say they very well might.
STAT10 min readPolitics
How Pharma, Under Attack From All Sides, Keeps Winning In Washington
It’s all President Trump and Democrats on Capitol Hill can agree on. So why hasn’t Washington lowered drug prices?
STAT3 min read
Opinion: I Get Asked A Lot About Longevity. It Helps That I’m 104
As scientists pursue longevity and anti-aging research, we wanted to hear from a centenarian on her life experience and thoughts on aging. So we called one.